bifidobacterium infantis
Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract and one of the 32 species that belong to the genus Bifidobacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants. When grown on general anaerobic medium, B. longum forms white, glossy colonies with a convex shape. B. longum is one of the most common bifidobacteria present in the gastrointestinal tracts of both children and adults. B. longum is non-pathogenic, is often added to food products, and its production of lactic acid is believed to prevent growth of pathogenic organisms. — Wikipedia
Clinical trial activity
101 trials · 147 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2002 (NCT00510978)
Timeline
Indications
Approved for
Studied for
- Abdominal Pain · Phase 2/Phase 3
- Acute-On-Chronic Liver Failure · Phase 2/Phase 3
- Adenomatous Polyposis Coli · Phase 2
- Aged · Early Phase 1
- Ascites · Phase 2
- Asthma · Phase 1/Phase 2
- Bipolar Disorder · Phase 2
- Celiac Disease · Phase 4
- Cognitive Dysfunction · Phase 4
- Colic · Phase 4
- Colitis, Ulcerative · Phase 2/Phase 3
- Crohn Disease · Phase 4
- Deglutition Disorders · Early Phase 1
- Dermatitis, Atopic · Phase 1
- Diabetes Mellitus · Phase 2
- Diarrhea · Phase 2/Phase 3
- Drug Resistance, Bacterial · Phase 2
- Esophageal and Gastric Varices · Phase 3
- Fatty Liver · Phase 1/Phase 2
- Fibrosis · Phase 4
- Food Hypersensitivity · Phase 1
- Gastroenteritis · Phase 3
- Gastrointestinal Microbiome · Phase 3
- General Surgery · Phase 3
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 2
- Hepatic Encephalopathy · Phase 4
- Hirschsprung Disease · Phase 2
- Hyperoxaluria · Phase 1/Phase 2
- Hypersensitivity · Phase 4
- Infant, Low Birth Weight · Phase 2/Phase 3
- Inflammation · Phase 2
- Inflammatory Bowel Diseases · Phase 3
- Intestinal Neoplasms · Phase 2/Phase 3
- Irritable Bowel Syndrome · Phase 4
- Kidney Failure, Chronic · Phase 2
- Klebsiella pneumoniae · Phase 1/Phase 2
- Liver Cirrhosis · Phase 2/Phase 3
- Neonatal Sepsis · Phase 3
- Nephrolithiasis · Phase 1/Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Osteoporosis · Phase 2
- Pediatrics · Phase 3
- Peritonitis · Phase 2/Phase 3
- Probiotics · Phase 4
- Psoriasis · Phase 1/Phase 2
- Scleroderma, Systemic · Phase 2
- Severe Acute Malnutrition · Phase 2
- Thinness · Phase 3
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBifidobacterium longum ↗
Also known as
- align
- bifidobacteria infantis
- bifidobacterium infantis
- bifidobacterium infantis 35624
- bifidobacterium infantis r0033
- bifidobacterium longum bv. infantis
- bifidobacterium longum infantis
- bifidobacterium longum ss. infantis r0033
- bifidobacterium longum ssp infantis r0033
- bifidobacterium longum subp. infantis r0033
- b. infantis 35624
- vsl #3
- vsl#3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06452199 | N/A | Jun 10, 2024 | Aarhus University, Gødstrup Hospital, Regionshospitalet Horsens, Statens Serum Institut, Technical University of Denmark, University of Copenhagen |
| NCT06102213 | Phase 2 | Sep 18, 2023 | Prolacta Bioscience |
| NCT05923333 | N/A | Jul 31, 2023 | Hoag Memorial Hospital Presbyterian, National Institutes of Health (NIH), Stellenbosch University, University of Cape Town, University of Washington |
| NCT05952076 | Phase 3 | Jul 3, 2023 | Bill and Melinda Gates Foundation |
| NCT05703659 | N/A | Mar 1, 2023 | University of Florida |
| NCT05767450 | N/A | Dec 16, 2022 | Vita-Salute University of Milano. Italy |
| NCT05129384 | N/A | Dec 8, 2021 | Evolve Biosystems, Inc., Sprim Consulting |
| NCT04769037 | N/A | Apr 22, 2021 | Gottfried Wilhelm Leibniz Universität Hannover, Helmholtz Centre for Infection Research, Katholieke Universiteit Leuven, Lund University, Medical University of Warsaw, Royal Victoria Infirmary, Newcastle upon Tyne, UK, Technical University of Dresden, Technical University of Munich |
| NCT04662619 | N/A | Dec 18, 2020 | Evolve Biosystems, Inc., Johnson and Johnson, University of Helsinki |
| NCT04769687 | Phase 2 | Nov 21, 2020 | University of Franche-Comté |
| NCT05461833 | N/A | Sep 1, 2020 | Bogomolets National Medical University, Government of Ukraine |
| NCT04374955 | N/A | Jul 31, 2020 | Halic University, Nobel Pharmaceuticals |
| NCT04172012 | Phase 3 | Mar 1, 2020 | Arctic University of Norway, Haydom Lutheran Hospital, Muhimbili University, University of Bergen, University of Stavanger |
| NCT04175392 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2019 | Oakland University |
| NCT05146921 | N/A | Jul 4, 2019 | University of London |
| NCT03994315 | N/A | Jun 10, 2019 | Coastal Pediatric Research, Evolve Biosystems, Inc. |
| NCT03939546 | N/A | May 31, 2019 | Evolve Biosystems, Inc., Orlando Health |
| NCT03893162 | N/A | May 31, 2019 | University of London |
| NCT04160767 | Phase 4 | Jan 30, 2019 | University of Milan |
| NCT03666572 | Phase 2 | Sep 15, 2018 | International Center for Diarrheal Disease Research |